There are several companies working in the field of cancer research. Seattle Genetics is occupying a unique place here. The CEO of this company is Clay Siegall. This is a company that is focused on several innovations it makes its advancements in the field of cancer therapy. Thus the stock prices of this company have tripled over the past five years. It also indicates the importance of this company in the field of cancer research.

Dr. Clay Siegall has a passion for improving the lives of those who are suffering from cancer. This has been with him ever since he started his career in biomedical studies. He is serving as the President, CEO, and even the Chairman of the Board at Seattle Genetics. Since 2002, Clay Siegall has been the chief executive officer of Seattle Genetics which he co-founded. He has over 20 years of experience. This is why he has been able to lead it to great advancements in the field of cancer research. He has managed to achieve several ground-breaking therapies which can be used for the treatment of cancer patients.

He holds a Ph.D. in Genetics from the George Washington University. Clay Siegall has a long list of professional accomplishments to his name. His career had started as a Senior Research Investigator with the Bristol-Myers Squibb Pharmaceutical Research Institute. After his promotion, he became the Principal Scientist over here. He moved on to become a Staff Fellow as well as Biotechnology Fellow at the National Cancer Institute. Next, Clay Siegall moved on to co-found Seattle Genetics.

Clay Siegall is known for his commitment towards conducting important research. He wants to implement all the latest developments in research methodologies. This is because of his consistent desire to help those who are suffering from cancer. His motivation is to alleviate their suffering. This passion has managed to help Clay Siegall in taking the company to new heights of success with regard to advancements in its research. Under the leadership of Clay Siegall, Seattle Genetics developed its first antibody-drug conjugates. These include ADCETRIS®. It was in 2011 that it could secure FDA approval.

Omar Boraie, Chair in Genomic Science, is helping to advance research in the field of precision medicine at Rutgers Cancer Institute of New Jersey. Endowed chairs are considered the gold standard in higher education and express the commitment by a university as well as ensure its support and advancement. Omar Boraie has made a $1.5 million pledge to support it and the Omar Boraie Chair is part of the University’s “18 Chair Challenge” campaign. This campaign involves an anonymous donor who provides a $1.5 million sum watch to each of the new chairs which results in $3 million endowment each.

Genomic science and precision medicine is changing how medical professionals handle cancer diagnosis and treatment and is still relatively new. During his most recent visit to the Union Address, President Obama announced the launch of a Precision Medicine Initiative developed to find a cure for cancer as well as other diseases.

According to Patch, Rutgers Cancer Institute was one of the very first facilities and the only one in the state to apply genomic sequencing as an approach to patient care. Genomic sequencing has helped to discover therapies for patients with poor prognoses, rare cancers, and limited treatment options. Physician-scientists at Rutgers Cancer Institute have made progress with precision medicine to help patients with cancers that have become resistant to treatments.

Dr.Boraie has been vital to the development of New Brunswick as the “Healthcare City.” and his support has had an immense impact on cancer research, as mentioned in the Newswire article, Omar Boraie Chair in Genomic Science Established at Rutgers Cancer Institute. Ganesan, MD, PhD, has been named to this chair. Dr.Ganesan is a medical oncologist regarded as an academic researcher and leader internationally, came to the Cancer Institute in 2005 from the Dana-Farber Cancer Institute at Harvard Medical School. He’s honored to be named the Omar Boraie Chair in Genomic Science and is helping to spark renewed hope in cancer patients and their families, through his research efforts.

Rutgers Cancer Institute of New Jersey is the first and only National Cancer Institute-designated Comprehensive Cancer Center in the state. It is dedicated to improving treatment, care, and dedication of patients, and is also serving as an education resource for the prevention of cancer. The physician-scientists at the center are committed to turning their discoveries into clinical practice and to bringing their research to life.

In January of 2013, Mirna Therapeutics appointed Seattle Genetics co-founder and CEO Clay Siegall, PhD. as a member of the Board of Directors. Mirna is a company focused om micro RNA in therapeutics, located in Austin, Texas. The company’s focus is on cancer research. The President and CEO of Mirna, Dr. Paul Lammers, hopes that Dr. Siegall can guide them in the development of their micro RNA-based process.

Clay Siegall, PhD. started Seattle Genetics in 1998. They have created antibody-based therapies for cancer patients who were not responding to other therapies. Antibody drug Conjugate (ADC) reduces toxic effects of chemotherapy and helps destroy tumors. There are currently several programs being used; for myeloid leukemia, and non-Hodgkin lymphoma. Dr. Siegall holds 15 patents and has authored over 70 reports.

Seattle Genetics is located in Bothell, Washington. They have partnered with Genentech, Bayer Pharmaceuticals Corporation, Curagen and Medummune on various projects. They share licenses with companies like Celldex Therapeutics, GlaxoSmithKline, AbbVIe Biotechnology, Pfizer, Genentech and more.

Before starting Seattle Genetics, Dr. Siegall, attended the University of Maryland, where he studied Zoology. He then attended George Washington University and earned a PhD. in Genetics. He then worked for the National Cancer Institute, National Institutes.

He is currently Chairman and CEO of Seattle Genetics and on the Board of Alder Pharmaceuticals, Washington Biotech, Biomedical Association, Fred Hutchinson Cancer Research Centre and Mirna Therapeutics. Dr. Siegall has helped Seattle Genetics secure more than $675 million for research, through public and private financing. The company had its initial public offering in 2001.